Poseida Therapeutics Gains; FDA Clears Lymphoma Treatment Trial

Poseida Therapeutics gains as much as 23% after announcing the FDA cleared its Investigational New Drug (IND) application for a drug designed to treat relapsed or refractory B-cell malignancies, a type of lymphoma.

• “We believe this represents the FDA’s first known IND clearance of an allogeneic dual CAR-T therapy targeting CD19 and CD20,” said Kristin Yarema, President, Cell Therapy at Poseida
• The drug, P-CD19CD20-ALLO1, targets CD19 and CD20 antigens and is being developed in partnership with Roche
• It will be evaluated in a Phase 1 multicenter study that will enroll as many as 70 adult patients with relapsed or ...